Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Renalytix ( (GB:RENX) ) has shared an update.
Renalytix reported first-half fiscal 2026 revenues of $1.6 million, up from $1.3 million a year earlier, as it expanded kidneyintelX.dkd deployment to 58 additional practice sites and five fully integrated EHR systems across key U.S. regions. The company also reduced its underlying EBITDA loss through cost discipline, began transitioning to a new laboratory to boost capacity and margins, and raised $9.5 million via an oversubscribed equity placing at a premium.
Post-period, Renalytix advanced talks with major U.S. diagnostic companies for a national distribution deal that could widen access and cut logistics costs, while progressing CE marking and pharma trial inclusion to support international and drug-development opportunities. Management reiterated expectations for about $4 million in full-year revenue, noting delays tied to the complexity of EMR integrations rather than demand, and forecast revenue acceleration in the second half as integrations mature and broader distribution gains traction.
The most recent analyst rating on (GB:RENX) stock is a Sell with a £2.00 price target. To see the full list of analyst forecasts on Renalytix stock, see the GB:RENX Stock Forecast page.
Spark’s Take on RENX Stock
According to Spark, TipRanks’ AI Analyst, RENX is a Neutral.
The score is primarily constrained by weak financial fundamentals (large ongoing losses, negative free cash flow, and negative equity). Technicals add further pressure due to a pronounced downtrend and negative momentum, with only limited offset from oversold indicators. Valuation provides little support because earnings are negative and dividend yield is unavailable.
To see Spark’s full report on RENX stock, click here.
More about Renalytix
Renalytix is an artificial intelligence-enabled in vitro diagnostics company focused on improving clinical management of kidney disease. Its flagship product, kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test for early-stage risk assessment in diabetic kidney disease, offered commercially in the U.S. and integrated into major EMR platforms and clinical guidelines.
Average Trading Volume: 876,330
Technical Sentiment Signal: Sell
Current Market Cap: £9.61M
See more insights into RENX stock on TipRanks’ Stock Analysis page.